Clinical trial
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib…
NCT03706365 · Eli Lilly and Company, Industry · Active, not recruiting
Key facts
| NCT number | NCT03706365 |
|---|---|
| Title | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer |
| Official title | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer |
| Acronym | CYCLONE 2 |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Abemaciclib, Placebo, Abiraterone acetate, Prednisone |
| Enrollment | 393 |
| Start date | Nov 26, 2018 |
| Primary completion | Jan 2, 2024 |
| Completion | Jun 1, 2026 |
| First posted | Oct 16, 2018 |
| Last update posted | Apr 20, 2025 |
| Countries | Australia, China, Denmark, France, Germany, Japan, Netherlands, Romania, South Korea, Spain, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: